Merck & Co Q2 EPS $(2.06) Beats $(2.17) Estimate, Sales $15.04B Beat $14.39B Estimate
Portfolio Pulse from Benzinga Newsdesk
Merck & Co reported Q2 losses of $(2.06) per share, beating the analyst consensus estimate of $(2.17) by 5.07%. This is a 210.16% decrease over earnings of $1.87 per share from the same period last year. The company also reported quarterly sales of $15.04 billion, beating the analyst consensus estimate of $14.39 billion by 4.50%. This is a 3.03% increase over sales of $14.59 billion the same period last year.
August 01, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Merck & Co's Q2 earnings and sales beat analyst estimates. However, EPS decreased by 210.16% compared to the same period last year.
While Merck & Co beat analyst estimates for Q2 earnings and sales, the significant decrease in EPS compared to the same period last year could potentially concern investors. This mixed result makes the short term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100